VBI Vaccines Inc

NASDAQ:VBIVUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

VBI Vaccines Inc. is a commercial stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology, The Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers, including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for corona virus disease include VBI-2901, VBI-2905, VBI-2902, and other. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2501 is its Prophylactic Candidate for Zika virus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.

Contact Information

Headquarters

160 Second Street, CambridgeCAMBRIDGE, MA, United States 02142

Phone

617-830-3031

Fax

---

Executives

Independent Chairman of the Board

Steven Gillis

President, Chief Executive Officer, Director

Jeffrey Baxter

Chief Financial Officer, Director, Head of Corporate Development

Nell Beattie

Chief Scientific Officer

David Anderson

Global Head of Manufacturing and SciVac General Manager

Avi Mazaltov